Aurobindo Pharma Q4 FY25: Revenue +10.6%, PAT flat

Why Aurobindo’s March-quarter numbers matter

Aurobindo Pharma reported a steady March-quarter performance for FY25, with revenue growth driven by its largest export markets while profitability remained largely unchanged. The company ended the quarter (Q4 FY25) with consolidated revenue from operations of ₹8,382 crore, compared with ₹7,580 crore in Q4 FY24. Profit after tax (PAT) came in at ₹903 crore, marginally lower than ₹907 crore a year earlier. The update is closely tracked because the US and Europe formulation businesses form the core of Aurobindo’s earnings profile. The quarter also showed a softer trend in certain Growth Markets, where the company cited price pressures and moderated performance in select regions.

Q4 FY25 headline performance

In Q4 FY25, Aurobindo’s revenue rose 10.6% year-on-year to ₹8,382 crore. Sequentially, the company also reported a 5.1% quarter-on-quarter increase in revenue, from ₹7,979 crore in Q3 FY25. PAT slipped 0.5% year-on-year to ₹903 crore. Another disclosure pegged net profit at ₹903.5 crore for the quarter ended March 31, 2025, indicating the same broad outcome: profit stayed almost flat despite higher sales. On a quarter-on-quarter basis, profit was stated to have risen around 7%.

US formulations: volumes and launches drive growth

The US formulations business remained the largest contributor in the quarter. Revenue from US formulations rose 13.5% year-on-year to ₹4,072 crore (also reported as $170 million). The company attributed the growth to higher volumes and new product launches, alongside a stable pricing environment. In one disclosure, the US was said to contribute 48.6% of consolidated revenue in Q4 FY25. The US market’s performance is important for investors because it tends to influence both revenue momentum and operating leverage for Indian generic manufacturers.

Europe formulations: stronger growth rate in Q4

Europe formulations revenue increased 17.2% year-on-year to ₹2,147 crore (also reported as €236 million). The company linked the rise to steady demand and capacity additions. Europe was also stated to account for 25.6% of consolidated revenue in the quarter. Separately, management commentary indicated the European operations were moving toward the USD 1 billion revenue milestone, underlining the strategic focus on scaling this geography.

Growth Markets: revenue decline amid price pressure

In contrast to the US and Europe, Growth Markets revenue declined 7.8% year-on-year to ₹786 crore. The company attributed the drop to price pressures and subdued performance in select regions. Growth Markets were reported to contribute 9.4% of consolidated revenue in Q4 FY25. The divergence across regions meant that overall consolidated growth was supported primarily by the developed-market formulations engine.

Other Q4 business lines: APIs, ARV and domestic

Aurobindo reported that Active Pharmaceutical Ingredients (APIs) revenue increased 5% year-on-year to ₹1,069 crore, accounting for 12.8% of consolidated revenue. The antiretroviral (ARV) segment recorded revenue growth of 29.4% year-on-year to ₹308 crore, contributing 3.7% to consolidated revenue. Domestic formulation sales were reported at ₹56 crore during the quarter. These numbers provide context on diversification, but the quarter’s direction was still largely determined by US and Europe formulations.

Margins: EBITDA margin contracts despite higher sales

Profitability was stable at the net level, but operating margin saw some pressure. EBITDA margin contracted by 88 basis points to 21.4% of revenue in Q4 FY25. The company also reported EBITDA of ₹1,792 crore at a 21.4% margin. In one report, the marginal decline in PAT was attributed to an increase in total expenses compared with the previous year. With revenue growing at a double-digit rate, the margin compression becomes a key point for investors monitoring the balance between growth, pricing, and cost inflation.

FY25 snapshot: revenue and profit growth led by the US

For the full financial year ended March 31, 2025, Aurobindo reported revenue from operations of ₹31,724 crore (also reported as ₹31,723.7 crore). Full-year net profit rose 9.9% year-on-year to ₹3,484 crore (also reported as ₹3,485.8 crore). By geography, the US accounted for nearly 40% of annual sales at ₹14,816 crore, while Europe and Growth Markets contributed ₹8,356 crore and ₹3,180 crore, respectively. The company also disclosed that FY25 formulations revenue grew 12.2% to ₹27,388 crore.

Balance sheet and regulatory pipeline highlights disclosed

Aurobindo also reported a shift to a net cash position of $12 million, transitioning from net debt of $14 million in December 2024. On the regulatory and product side, it highlighted biosimilar approvals in Europe and said the US business included nine new ANDA filings. While these disclosures do not directly change the quarter’s reported revenue and profit, they add context on pipeline activity and financial flexibility.

Key numbers table

What investors will track next

The quarter reinforced Aurobindo’s dependence on developed-market formulations for growth, particularly the US and Europe. At the same time, the decline in Growth Markets and the EBITDA margin contraction highlight the sensitivity of profitability to pricing and costs. The company’s FY25 outcome showed higher annual revenue and profit, alongside geographic concentration where the US remains the single largest contributor. Future updates on product launches, ANDA filings, and Europe expansion will be important for tracking whether growth sustains without further margin pressure.

Conclusion

Aurobindo Pharma closed Q4 FY25 with revenue of ₹8,382 crore, led by double-digit growth in the US and Europe formulations businesses, while PAT stayed near ₹903 crore and EBITDA margin moderated to 21.4%. The next focus will be on how regional pricing trends and product momentum shape margins and growth in the coming quarters.